Moneycontrol.com | Celgene Corporation gets USFDA approves for REVLIMID Moneycontrol.com The approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or ... FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma Revlimid Gains New Lymphoma Indication FDA clears Celgene's sNDA for mantle cell lymphoma drug candidate |
